Your browser doesn't support javascript.
loading
Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011.
Niang, Mbayame Nd; Sugimoto, Jonathan D; Diallo, Aldiouma; Diarra, Bou; Ortiz, Justin R; Lewis, Kristen D C; Lafond, Kathryn E; Halloran, M Elizabeth; Widdowson, Marc-Alain; Neuzil, Kathleen M; Victor, John C.
Afiliação
  • Niang MN; Institut Pasteur de Dakar, Dakar, Senegal.
  • Sugimoto JD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Diallo A; Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, Washington, USA.
  • Diarra B; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Ortiz JR; VITROME, Institut de Recherche Pour le Développement, Dakar, Senegal.
  • Lewis KDC; VITROME, Institut de Recherche Pour le Développement, Dakar, Senegal.
  • Lafond KE; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Halloran ME; PATH, Seattle, Washington, USA.
  • Widdowson MA; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Neuzil KM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Victor JC; Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Clin Infect Dis ; 72(12): e959-e969, 2021 06 15.
Article em En | MEDLINE | ID: mdl-33165566
ABSTRACT

BACKGROUND:

We report results of years 2 and 3 of consecutive cluster-randomized controlled trials of trivalent inactivated influenza vaccine (IIV3) in Senegal.

METHODS:

We cluster-randomized (11) 20 villages to annual vaccination with IIV3 or inactivated poliovirus vaccine (IPV) of age-eligible residents (6 months-10 years). The primary outcome was total vaccine effectiveness against laboratory-confirmed influenza illness (LCI) among age-eligible children (modified intention-to-treat population [mITT]). Secondary outcomes were indirect (herd protection) and population (overall community) vaccine effectiveness.

RESULTS:

We vaccinated 74% of 12 408 age-eligible children in year 2 (June 2010-April 11) and 74% of 11 988 age-eligible children in year 3 (April 2011-December 2011) with study vaccines. Annual cumulative incidence of LCI was 4.7 (year 2) and 4.2 (year 3) per 100 mITT child vaccinees of IPV villages. In year 2, IIV3 matched circulating influenza strains. The total effectiveness was 52.8% (95% confidence interval [CI], 32.3-67.0), and the population effectiveness was 36.0% (95% CI, 10.2-54.4) against LCI caused by any influenza strain. The indirect effectiveness against LCI by A/H3N2 was 56.4% (95% CI, 39.0-68.9). In year 3, 74% of influenza detections were vaccine-mismatched to circulating B/Yamagata and 24% were vaccine-matched to circulating A/H3N2. The year 3 total effectiveness against LCI was -14.5% (95% CI, -81.2-27.6). Vaccine effectiveness varied by type/subtype of influenza in both years.

CONCLUSIONS:

IIV3 was variably effective against influenza illness in Senegalese children, with total and indirect vaccine effectiveness present during the year when all circulating strains matched the IIV3 formulation. CLINICAL TRIALS REGISTRATION NCT00893906.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana Limite: Child / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2021

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana Limite: Child / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2021